No Data
No Data
Jiangsu Hengrui Pharmaceuticals (600276.SH) has received a notification of approval for clinical trials of a drug.
Jiangsu Hengrui Pharmaceuticals (stock code: 600276.SH) announced that the company and its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. have received the drug clinical trial approval notices for HRS-1358 tablets, HRS-8080 tablets, and HRS-6209 capsules issued by the National Medical Products Administration. Clinical trials will be conducted in the near future.
Individual Investors Own 33% of Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Shares but Private Companies Control 46% of the Company
Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 48.32 Yuan From 51.12 Yuan, Keeps at Neutral
Jiangsu Hengrui Medicine Gets Clinical Trial Approval for Liver Disease Treatment
Jiangsu Hengrui Pharmaceuticals (600276.SH): Hydroxyethylsulfonate Dalsilepin tablets and HRS-1358 tablets have obtained drug clinical trial approval.
On July 21st, Gelunhui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) and its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. recently received the Approval Notice for Clinical Trials of Hydroxyethanesulfonic Acid Daxcelipine Tablets and HRS-1358 Tablets issued by the National Medical Products Administration, and will conduct clinical trials in the near future. Hydroxyethanesulfonic Acid Daxcelipine Tablets (trade name: Airicon) has been approved for two indications, respectively: in December 2021, it was approved for use in combination with Fluvestrant for Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer patients who have undergone endocrine therapy.
Zhao Bei's second-quarter report for ICBC Credit Suisse Fund has been released! Jiangsu Hengrui Pharmaceuticals (600276.SH) is the top holding.
On July 18th, the fund under Zhao Bei's management at ICBC Credit Suisse Fund released its Q2 report for 2024.
No Data